Related Experiment Video
Updated: May 22, 2026
07:08
Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
Published on: February 27, 2018
Therapy in Huntington's disease: where are we?
1Struthers Parkinson's Center, 6701 Country Club Drive, Golden Valley, MN 55427, USA. nancem@parknicollet.com
Current Neurology and Neuroscience Reports
|May 1, 2012
Summary
Huntington's disease (HD) lacks disease-modifying treatments, but symptom management is available. Future diagnosis may combine imaging and biomarkers as neurodegeneration insights evolve.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Huntington's disease (HD) is a genetic neurodegenerative disorder.
- Despite gene discovery nearly 20 years ago, effective disease-modifying treatments remain elusive as of 2012.
- Current management focuses on alleviating common HD symptoms through pharmacologic and nonpharmacologic means.
Purpose of the Study:
- To review the current state of Huntington's disease research and clinical practice.
- To discuss the evolving understanding of neurodegeneration onset in HD.
- To project future diagnostic approaches for Huntington's disease.
Main Methods:
- Review of clinical research and therapeutic strategies for Huntington's disease.
- Analysis of recent studies on gene-positive individuals in pre-symptomatic stages.
- Discussion of potential shifts in diagnostic paradigms.
Main Results:
- No disease-modifying treatments for Huntington's disease were established by 2012.
- Symptomatic treatments are available for many common manifestations of HD.
- Research indicates neurodegeneration begins before clinical diagnosis in gene-positive individuals.
Conclusions:
- The perception of neurodegeneration onset in Huntington's disease is being redefined by early-stage research.
- Future diagnosis of HD may integrate advanced imaging, clinical examination, and biomarker analysis.
- The advent of disease-modifying therapies will necessitate a more comprehensive diagnostic approach.
Related Concept Videos
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...